39 completed, 3 terminated, 1 not yet recruiting, 1 withdrawn. 44 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 44 | Completed 39, Terminated 3, Not yet recruiting 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 2 |
Follow Hepatitis B Vaccines: new trials by email Literature Review of Hepatitis B Vaccines trials Research Report on Hepatitis B Vaccines
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma) Recombinant Hepatitis B new Bulk vaccine, DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine, Recombinant Hepatitis B vaccine (Registered BioFarma) - Diphtheria Vaccine Adverse Reaction, Tetanus Vaccine Adverse Reaction | Phase 3 | Withdrawn | PT Bio Farma | 2025-12-01 | 2025-06-05 | |
| Optimal Timing of Hepatitis B Vaccination After Transplants hepatitis B vaccine - Transplant-Related Disorder, Hepatitis B Virus Infection | Phase 3 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 1500 | 2025-06-01 | 2025-03-21 |
| Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers RSVt vaccine, Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine, Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine - RSV Immunization | Phase 3 | Terminated | Sanofi Pasteur, a Sanofi Company | 2226 | 2024-05-13 | 2026-10-05 |
| A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination (V419-013) HBVAXPRO™ - Hepatitis B | Phase 3 | Completed | Merck Sharp & Dohme LLC | 207 | 2020-09-02 | 2022-07-27 |
| Protectivity and Safety Following Recombinant Hepatitis B Vaccine Recombinant Hepatitis B vaccine, Recombinant Hepatitis B (Bio Farma) - Immunogenicity | Phase 2 / Phase 3 | Completed | PT Bio Farma | 536 | 2019-09-11 | 2022-09-19 |
| A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION) Prevnar 13™, V114, RotaTeq™ - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 900 | 2018-10-18 | 2023-01-17 |
| Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Measles, Mumps, and Rubella Virus Vaccine Live - Healthy Volunteers (Meningococcal Infection) | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 525 | 2018-10-17 | 2023-10-19 |
| Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine, Meningococcal group B vaccine, Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine - Healthy Volunteers (Meningococcal Infection) | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 788 | 2018-10-10 | 2023-11-07 |
| Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers Meningococcal Polysaccharide (Serogroups A,C,Y and W) Tetanus Toxoid Conjugate vaccine MenACYW conjugate vaccine, Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Meningococcal Polysaccharide (serogroups A,C,Y and W-135) Diphtheria Toxoid Conjugate Vaccine - Healthy Volunteers (Meningococcal Infection) | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 950 | 2018-10-04 | 2024-06-25 |
| Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine), Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®), Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine - Healthy Volunteers (Meningococcal Infection) | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 2797 | 2018-09-17 | 2023-12-14 |
| Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts Quadrivalent HPV vaccine, Hepatitis B vaccine - Genital Warts | Phase 3 | Completed | University of Pretoria | 52 | 2018-07-01 | 2026-01-23 |
| Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US MenACYW conjugate vaccine, MenACYW-135 conjugate vaccine, DTaP-IPV//Hib vaccine - Healthy Volunteers (Meningococcal Infection) | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 2627 | 2018-04-25 | 2024-10-15 |
| This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine Rotarix, Pediarix, Hiberix - Rotavirus Infection, Rotavirus Vaccines | Phase 3 | Completed | GlaxoSmithKline | 1280 | 2017-09-14 | 2020-12-29 |
| Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine HEPLISAV, Engerix-B - Healthy | Phase 3 | Completed | Dynavax Technologies Corporation | 8374 | 2014-04-01 | 2019-03-20 |
| DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants DTaP-IPV-Hep B-PRP~T combined vaccine, DTaP-IPV//PRP~T and Hepatitis B vaccine - Diphtheria, Tetanus | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 310 | 2014-03-01 | 2017-04-26 |
| Study of the Immunogenicity and Safety of a Challenge Dose of HBVAXPRO in Healthy Children Vaccinated 10 Years Ago With 3 Doses of HEXAVAC or INFANRIX HEXA HBVAXPRO 5µg - Virus Diseases, Hepatitis B | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 751 | 2014-01-01 | 2017-09-11 |
| Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination Hexavalent vaccine, NeisVac-C, Prevenar 13 - Neisseria Meningitidis, Bacterial Infections | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 350 | 2013-04-01 | 2017-09-11 |
| Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B Tenofovir, Peginterferon-alfa 2a and tenofovir - Hepatitis B | Phase 3 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 201 | 2012-11-01 | 2023-04-28 |
| Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis HBV vaccine - Hepatitis B, Cirrhosis | Phase 3 | Completed | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 112 | 2012-09-07 | 2018-05-14 |
| Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062) 2XP HEPTAVAX™-II SC, 1XP HEPTAVAX™-II SC, 2XP HEPTAVAX™-II IM - Hepatitis B | Phase 3 | Completed | Merck Sharp & Dohme LLC | 722 | 2011-11-29 | 2018-07-18 |
Showing 20 of 44. Sign in to see all of them.
Hepatitis B (24) · Meningococcal Infections (8) · Haemophilus Infections (5) · Hepatitis (5) · Diphtheria (4) · Meningitis, Meningococcal (3) · Otitis Media (3) · Poliomyelitis (3) · Streptococcal Infections (3) · Tetanus (3) · Whooping Cough (3) · Kidney Failure, Chronic (2) · Pneumococcal Infections (2) · Pneumonia (2) · Renal Insufficiency (2)
Sanofi Pasteur, a Sanofi Company (11) · Merck Sharp & Dohme LLC (6) · Dynavax Technologies Corporation (5) · GlaxoSmithKline (5) · Novartis Vaccines (3) · Jiangsu Province Centers for Disease Control and Prevention (2) · PT Bio Farma (2) · Emergent BioSolutions (1) · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · LG Life Sciences (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · National Institute on Drug Abuse (NIDA) (1) · Pfizer (1)
United States (14) · Puerto Rico (5) · Canada (4) · Finland (4) · China (3) · Germany (3) · Argentina (2) · Colombia (2) · Indonesia (2) · Italy (2) · Mexico (2) · South Korea (2) · Spain (2) · Turkey (Türkiye) (2) · Australia (1)
Anna Lok, MD (1) · Averell Sherker, MD (1) · Eddy Fadlyana, MD (1) · Edward Doo, MD (1) · Feng-Cai Zhu, M.D. (1) · Feng-Cai Zhu, Master (1) · Fubao Ma, Doctor (1) · Gerald Winnan, MD (1) · Greta G Dreyer, MMed(O&G)PhD (1)
PMID 34986178, PMID 20728932, PMID 20936979, PMID 21552183, PMID 22075088, PMID 22094635, PMID 22161542, PMID 22170543, PMID 22789511, PMID 23152368, PMID 23158882, PMID 23727002, PMID 23727422, PMID 23887167, PMID 24118636, PMID 24287186, PMID 24498033, PMID 24631093, PMID 24681228, PMID 25127244, PMID 25483566, PMID 25738667, PMID 25996838, PMID 26126668, PMID 26144895, PMID 26284652, PMID 27125273, PMID 27939054, PMID 28624307, PMID 29289383, PMID 29503110, PMID 29553862, PMID 30145098, PMID 30471953, PMID 31024978, PMID 31122856, PMID 31431412, PMID 35653552, PMID 36522265, PMID 36599136, PMID 36728214, PMID 36963815, PMID 38387470, PMID 39478672, PMID 41337697, PMID 41489614, PMID 41792337, PMID 42642862
2008 (2), 2018 (2), 2019 (2), 2009 (1), 2016 (1), 2017 (1), M01RR000040 (1), P01HL009011 (1), P30DK050306 (1), U01DK082843 (1), U01DK082863 (1), U01DK082864 (1), U01DK082866 (1), U01DK082867 (1), U01DK082871 (1)